A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer

计划入组 30 人 · 首次发布于 2026 年 8 月 24 日

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

计划入组 65 人 · 首次发布于 2025 年 9 月 30 日

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

计划入组 87 人 · 首次发布于 2026 年 8 月 11 日

HER2+ Breast Cancer(Diakonos)

oncology program (HER2+ breast cancer)

undisclosed epigenetic target therapeutic (metastatic breast cancer)

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

International Breast Cancer Research Foundation

United States

FDA Approves Roche's Companion Diagnostic for HER2-Ultralow Metastatic Breast Cancer

Enhertu Approved for HER2-Low and HER2-Ultralow Metastatic Breast Cancer

CHMP Recommends ENHERTU® Approval for HER2 Low/Ultralow Metastatic Breast Cancer in EU